造血干祖细胞基因治疗用于Hurler综合征
这项正在进行的开放研究纳入8例缺乏合适异基因供体且发育商或智商高于70的Hurler综合征(MPSIH)患儿,给予经慢病毒载体体外转导IDUA基因的自体造血干祖细胞,主要终点为安全性和血IDUA活性超生理水平纠正,中期结果显示代谢纠正广泛且认知运动稳定。
要点
- 8例MPSIH患儿接受自体HSPC基因治疗,中位随访2.10年,安全性特征与自体造血干细胞移植已知情况相似。
- 所有患者均实现基因纠正细胞的快速持续植入,1个月内血IDUA活性达超生理水平并维持至末次随访。
- 可评估的5例中4例尿GAG排泄在12个月降至正常水平,脑脊液IDUA活性由不可测转为可测并伴局部GAG清除。
核心结论
- 在MPSIH患者中给予HSPC基因治疗实现了外周组织和中枢神经系统的广泛代谢纠正。
研究设计与样本
- 正在进行的开放研究,纳入8例MPSIH患儿,入组时缺乏合适异基因供体且发育商或智商评分高于70。
- 患儿接受清髓预处理后,输注经编码α-L-艾杜糖醛酸酶(IDUA)的慢病毒载体体外转导的自体造血干祖细胞(HSPCs)。
- 主要终点为安全性和血IDUA活性纠正至超生理水平,次要和探索性终点包括溶酶体贮积物清除、骨骼和神经生理发育,计划研究时长5年。
主要发现
- HSPC基因治疗时患儿平均(±SD)年龄为1.9±0.5岁,中位随访2.10年。
- 所有患者均实现基因纠正细胞的快速持续植入,1个月内血IDUA活性达超生理水平并维持至末次随访。
- 可评估的5例患者中4例尿GAG排泄在12个月降至正常水平。
- 脑脊液中先前检测不到的IDUA活性在基因治疗后变为可检测,并与局部GAG清除相关。
- 患者认知表现稳定,运动技能稳定并与持续运动发育相符,脑和脊柱MRI表现改善或稳定,关节僵硬减轻,生长正常并与世界卫生组织生长曲线一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文报告的是中期结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Allogeneic hematopoietic stem-cell transplantation is the standard of care for Hurler syndrome (mucopolysaccharidosis type I, Hurler variant [MPSIH]). However, this treatment is only partially curative and is associated with complications. METHODS: We are conducting an ongoing study involving eight children with MPSIH. At enrollment, the children lacked a suitable allogeneic donor and had a Developmental Quotient or Intelligence Quotient score above 70 (i.e., none had moderate or severe cognitive impairment). The children received autologous hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with an α-L-iduronidase (IDUA)-encoding lentiviral vector after myeloablative conditioning. Safety and correction of blood IDUA activity up to supraphysiologic levels were the primary end points. Clearance of lysosomal storage material as well as skeletal and neurophysiological development were assessed as secondary and exploratory end points. The planned duration of the study is 5 years. RESULTS: We now report interim results. The children's mean (±SD) age at the time of HSPC gene therapy was 1.9±0.5 years. At a median follow-up of 2.10 years, the procedure had a safety profile similar to that known for autologous hematopoietic stem-cell transplantation. All the patients showed prompt and sustained engraftment of gene-corrected cells and had supraphysiologic blood IDUA activity within a month, which was maintained up to the latest follow-up. Urinary glycosaminoglycan (GAG) excretion decreased steeply, reaching normal levels at 12 months in four of five patients who could be evaluated. Previously undetectable levels of IDUA activity in the cerebrospinal fluid became detectable after gene therapy and were associated with local clearance of GAGs. Patients showed stable cognitive performance, stable motor skills corresponding to continued motor development, improved or stable findings on magnetic resonance imaging of the brain and spine, reduced joint stiffness, and normal growth in line with World Health Organization growth charts. CONCLUSIONS: The delivery of HSPC gene therapy in patients with MPSIH resulted in extensive metabolic correction in peripheral tissues and the central nervous system. (Funded by Fondazione Telethon and others; ClinicalTrials.gov number, NCT03488394; EudraCT number, 2017-002430-23.).
引用
- Gentner B, Tucci F, Galimberti S, et al. Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome. N Engl J Med. 2021. PMID: 34788506. doi:10.1056/NEJMoa2106596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。